文献速递中医内科中药与中成药合理使用

常规西药联合中药降低慢阻肺患者肺癌风险:全国回顾性队列研究

Conventional Western Treatment Combined With Chinese Herbal Medicine Alleviates the Progressive Risk of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study.
PubMed 文献 · Front Pharmacol · 2019-09-13

该研究基于台湾全民健康保险研究数据库,纳入2000至2010年新诊断慢阻肺的81,780名成人,经倾向匹配后每组2,682例,比较接受与未接受中药治疗者的肺癌发生率。结果显示中药组肺癌风险显著更低(aHR=0.36,95%CI=0.24-0.53,p<0.001),且年龄增长与肺癌风险升高相关。

要点

  • 慢阻肺患者在接受常规西药治疗基础上联用中药,肺癌风险显著降低(aHR=0.36)。
  • 年龄40-59岁和≥60岁患者肺癌风险分别为18-39岁者的5.32倍和16.75倍。
  • 最常用单味药为浙贝母,最常用方剂为小青龙汤。

核心结论

  • 中药作为慢阻肺治疗的辅助疗法可能降低该脆弱人群的肺癌风险。

研究设计与样本

  • 全国性回顾性队列研究,基于台湾全民健康保险研究数据库,纳入2000至2010年新诊断慢阻肺的81,780名≥18岁成人,其中11,180例接受中药治疗、23,319例未接受,经排除缺失人口学信息者后每组各2,682例。

主要发现

  • 接受中药治疗的慢阻肺患者肺癌风险显著低于未接受者(aHR=0.36,95%CI=0.24-0.53,p<0.001)。
  • 与18-39岁患者相比,40-59岁患者肺癌风险显著升高(aHR=5.32,95%CI=2.19-12.94,p<0.001),≥60岁患者风险更高(aHR=16.75,95%CI=7.54-37.23,p<0.001)。
  • 中药使用与肺癌累积发生率降低的趋势相关(p<0.001)。
  • 在降低慢阻肺患者肺癌风险最常用的10种单味药和方剂中,浙贝母为最常用单味药,小青龙汤为最常用方剂。

临床怎么用

  • 在常规西药治疗慢阻肺的基础上,可考虑联用中药作为辅助治疗以潜在降低肺癌风险。
  • 对40岁以上慢阻肺患者应尤其关注肺癌风险,中药联用可能带来额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and purpose: Lung cancer has high global incidence and mortality rates. Chronic obstructive pulmonary disease (COPD) is strongly associated with lung cancer and is an independent risk factor for lung cancer with or without smoking. Chinese herbal medicines (CHMs) are used to treat COPD. This study sought to determine whether CHM treatment effectively decreases the incidence of lung cancer in COPD patients receiving conventional Western medical treatment. Methods: Records obtained from the National Health Insurance Research Database (NHIRD) were used to identify 81,780 adults aged ≥18 years newly diagnosed with COPD in Taiwan between 2000 and 2010. Among them, 11,180 received CHMs after COPD diagnosis and 23,319 did not (non-CHM). After excluding patients with missing basic demographic information, each group consisted of 2,682 patients. Statistical methods analyzed the baseline characteristics for both groups and we performed a Cox proportional hazard regression analysis to examine the incidence of lung cancer. The cumulative incidence of lung cancer in COPD patients with or without CHM treatment was calculated by the Kaplan-Meier method. The association between herbs and formulas was examined by NodeXL to perform a network analysis of CHM. Results: COPD patients using CHM had a lower risk for lung cancer (adjusted hazards ratio [aHR] = 0.36, 95% confidence interval [CI] = 0.24-0.53, p < 0.001). Older age was associated with a higher risk of lung cancer: patients aged 40-59 years (aHR = 5.32, 95% CI = 2.19-12.94, p < 0.001) and those aged ≥60 years (aHR = 16.75, 95% CI = 7.54-37.23, p < 0.001) were at significantly greater risk compared with patients aged 18-39 years. CHM use was associated with a trend for a lower cumulative incidence of lung cancer compared with non-CHM use (p < 0.001). Among the 10 most commonly used single herbs and formulas used to decrease the risk of lung cancer in COPD patients, Fritillariae thunbergii was the most commonly used single herb and Xiao Qing Long Tang the most commonly used formula. Conclusion: The findings from this nationwide retrospective cohort study indicate that CHM as adjunctive therapy in COPD treatment regimens may reduce the risk of lung cancer in this vulnerable patient population.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lin TH, Chen SI, Su YC, et al. Conventional Western Treatment Combined With Chinese Herbal Medicine Alleviates the Progressive Risk of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study. Front Pharmacol. 2019. PMID: 31572178. doi:10.3389/fphar.2019.00987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。